ATryn is that the initial recombinant antithrombin product approved within the world and also the initial antithrombin product that has been approved through the centralized procedure within the Europe. it’s currently additionally the primary recombinant antithrombin product approved by the bureau.
Submit your review
Applies to antithrombin (recombinant): parenteral injection
Side effects include:
Hemorrhage, infusion site reactions.
For intravenous use only after reconstitution The dosage of ATryn is individualized for each patient. Treatment goal is to restore and maintain functional antithrombin (AT) activity levels between 80% - 120% (0.8 - 1.2 IU/mL) of normal. Administer loading dose as a 15-minute intravenous infusion immediately followed by continuous infusion of the maintenance dose. AT activity monitoring is required for proper treatment. Check AT activity once or twice per day and adjust dose accordingly. Continue administration of ATryn until adequate follow-on anticoagulation has been established. Store at 2-8°C (36-46°F). Discard any unused portion.